SEngine Precision Medicine is a Seattle-based company that specializes in personalized cancer treatments and drug development. Their innovative approach combines 3D organoid technology and proprietary algorithms to provide more effective treatment options and accelerate drug development. By testing over 200 cancer drugs against a patient's unique tumor organoid, SEngine's high-throughput technology decodes the most effective and least toxic treatment options that DNA sequencing alone cannot reveal. Additionally, the company leverages aggregated test results to develop new cancer-fighting drugs.
SEngine Precision Medicine's PARIS Test is a game-changer in cancer care, delivering effective treatment options for solid tumors up to 80% of the time, compared to the estimated 15% prediction rate of DNA sequencing alone. As a CLIA-certified lab, SEngine is the only lab that provides actionable reports directly to oncologists, empowering patients and healthcare professionals with more informed treatment decisions. With a focus on improving patient outcomes today and transforming cancer care tomorrow, SEngine Precision Medicine is making a significant impact on the lives of cancer patients.
Generated from the website